These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32450176)

  • 1. Galectins as potential pharmacological targets in renal injuries of diverse etiology.
    Gu M; Mei X; Zhao Y
    Eur J Pharmacol; 2020 Aug; 881():173213. PubMed ID: 32450176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Galectins in Tumors and in Clinical Immunotherapy.
    Chou FC; Chen HY; Kuo CC; Sytwu HK
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Galectin-3 in the Kidneys.
    Chen SC; Kuo PL
    Int J Mol Sci; 2016 Apr; 17(4):565. PubMed ID: 27089335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectins in kidney development.
    Hughes RC
    Glycoconj J; 2002; 19(7-9):621-9. PubMed ID: 14758088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role and translational implication of galectins in arthritis pathophysiology and treatment: A systematic literature review.
    Salamanna F; Veronesi F; Frizziero A; Fini M
    J Cell Physiol; 2019 Feb; 234(2):1588-1605. PubMed ID: 30144075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster.
    Saussez S; Nonclercq D; Laurent G; Wattiez R; André S; Kaltner H; Gabius HJ; Kiss R; Toubeau G
    Histochem Cell Biol; 2005 Jan; 123(1):29-41. PubMed ID: 15609042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Galectins in Multiple Myeloma.
    Storti P; Marchica V; Giuliani N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of selected blood and immune cell responses to carbohydrate-dependent surface binding of proto- and chimera-type galectins.
    Timoshenko AV; Gorudko IV; Maslakova OV; André S; Kuwabara I; Liu FT; Kaltner H; Gabius HJ
    Mol Cell Biochem; 2003 Aug; 250(1-2):139-49. PubMed ID: 12962152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of galectin-3 in autoimmune and non-autoimmune nephropathies.
    Saccon F; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
    Autoimmun Rev; 2017 Jan; 16(1):34-47. PubMed ID: 27666815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of sugar chain recognition by galectins and its involvement in disease-associated glycosylation.
    Arikawa T; Simamura E; Shimada H; Nakamura T; Hatta T; Shoji H
    Congenit Anom (Kyoto); 2014 May; 54(2):77-81. PubMed ID: 24450300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering galectin-glycan interactions for immunotherapy and immunomodulation.
    Farhadi SA; Hudalla GA
    Exp Biol Med (Maywood); 2016 May; 241(10):1074-83. PubMed ID: 27229902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesis.
    Yan H; Xu J; Xu Z; Yang B; Luo P; He Q
    Biomed Pharmacother; 2021 Nov; 143():112115. PubMed ID: 34488081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-9 in cancer therapy.
    Fujihara S; Mori H; Kobara H; Rafiq K; Niki T; Hirashima M; Masaki T
    Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):130-7. PubMed ID: 23514536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present).
    Sethi A; Sanam S; Alvala R; Alvala M
    Expert Opin Ther Pat; 2021 Aug; 31(8):709-721. PubMed ID: 33749494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of targeting galectins - A biomaterials-focused perspective.
    Martin-Saldaña S; Chevalier MT; Pandit A
    Biomaterials; 2022 Jul; 286():121585. PubMed ID: 35623267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions.
    Sörme P; Kahl-Knutsson B; Huflejt M; Nilsson UJ; Leffler H
    Anal Biochem; 2004 Nov; 334(1):36-47. PubMed ID: 15464951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectins as potential emerging key targets in different types of leukemia.
    Zheng Y; Feng W; Wang YJ; Sun Y; Shi G; Yu Q
    Eur J Pharmacol; 2019 Feb; 844():73-78. PubMed ID: 30452910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed ischaemic preconditioning in the presence of galectin-9 protects against renal ischaemic injury through a regulatory T-cell dependent mechanism.
    Zhang BY; Fang Y; Jiao XY; Wu S; Cai JR; Zou JZ; Ding XQ
    Nephrology (Carlton); 2016 Oct; 21(10):828-34. PubMed ID: 26609639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectins at a glance.
    Johannes L; Jacob R; Leffler H
    J Cell Sci; 2018 May; 131(9):. PubMed ID: 29717004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-carbohydrate strategies to inhibit lectin proteins with special emphasis on galectins.
    Sethi A; Sanam S; Alvala M
    Eur J Med Chem; 2021 Oct; 222():113561. PubMed ID: 34146913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.